Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: PMBHF )

0.0690 UNCHANGED
Streaming Delayed Price Updated: 11:06 AM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0690
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0690
Today's Range 0.0690 - 0.0690
52wk Range 0.0536 - 0.5400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized... 
Via Benzinga
PharmAla Begins Trading on OTCQB
From PharmAla Biotech
Via GlobeNewswire

Performance

YTD
-77.63%
-77.63%
1 Month
-23.16%
-23.16%
3 Month
-57.20%
-57.20%
6 Month
-70.45%
-70.45%
1 Year
-77.63%
-77.63%

More News

Read More
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Via Benzinga
PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment
Via Benzinga
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
From PharmAla Biotech
Via GlobeNewswire
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
Via Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
Via Benzinga
PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment
Via Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Via Benzinga
Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M
Via Benzinga
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
Via Benzinga
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
From PharmAla Biotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.